Podcasts about cancer centers

Dr. Bill Putnam, Medical Director, joins JMN and shares how Baptist MD Anderson Cancer Center has evolved and provided cutting edge cancer treatment resources for a decade - and how they work to meet the needs in various area communities, with campuses at Baptist Downtown, Baptist South, Baptist Clay, and more.

Joel Laton, Lead Chaplain, joins JMN to share his role and the role of his team of chaplains in the holistic treatment process at Baptist MD Anderson Cancer Center. Spiritual and pastoral care extends to spouses and family members, offering support and guidance for the "person," during clinical care processes.

Dr. Laila Samiian, Chief of Breast Surgical Oncology, discusses the importance of screening and prevention resources for breast health, as Breast Cancer Awareness month wraps up. She shares how care processes vary with the patient's age, breast density, and individual needs, as each patient's cancer is different.

Dr. Gordon Guo, Radiation Oncologist, discusses the facts and the myths regarding prostate cancer. Ex: Fact - 1 in 8 men will develop prostate cancer; Myth - If you have no symptoms, you don't have the disease. Dr. Guo also speaks to what patients need to know about testing, diagnosis, and treatment protocols.

Theresa Pola, Outpatient Dietitian, joins JMN to discuss the role of lifestyle and diet in cancer prevention, treatment, and recovery. She also speaks to how nutritional needs can change relative to treatment protocols, and the impacts that exercise, relaxation, and stress management can have on overall health.

Becky Ness, Oncology Social Worker, joins JMN to discuss ways cancer can impact family dynamics during and after treatment. She advocates support groups, communication, and social work teaching cooperation and prioritization to help families rally in care and support wihtout their o the patient's individual identities being subsumed by cancer. Her approach is that whole-person healing is the goal, not just clinical resolution.

Dr. Kim LaBree, Assistant Administator of Patient Services, addresses a number of listener questions regarding local area health concerns, diagnostic processes, and Baptist MD Anderson Cancer Center care resources. Se asserts that the most important part of preventative or clinical care is routine checkups with your primary care physician. If you need to establish a primary care physician, Baptist invites you to contact them at 904-202-4YOU (4968).

LeeAnn Mengel, Vice President Administrator, joins JMN to recap Baptist MD Anderson Cancer Center's evolution over the past ten years, and looks toward continued expansion, growing resources, and continuing innovative holistic care.

Dr. Eric Peters and Dr. Hamid Mirshahidi of Loma Linda University Cancer Center discuss theranostics.

“Another sign is not the answer—it dilutes the message.” - Corinn Soro Today on the pod, Cheryl sits down—virtually—with Senior Planner and Interior Designer Corinn Soro of Roswell Park Comprehensive Cancer Center in Buffalo, NY for a deep dive into wayfinding that actually works: why “visual pollution” erodes attention, how de-crapification clarifies intent, and where evidence-based choices can transform the patient journey from disorientation to ease.  Expect real examples—subway-style maps that set expectations at a glance, pictograms that land when words won't, and donor walls designed to evolve rather than date out—plus the small, cumulative tweaks that lower stress for visitors and staff alike.  Today's conversation is about design as reassurance, translating research into decisions that cut through noise and hand back control the moment someone walks through the door. What We Cover A 17-year-old's spark: geriatric care, neuroplasticity, and the built environment London roots: learning research methods alongside OTs and PTs; universal design for all bodies Evidence-Based Design in action: NICU decisions (sound, circadian light, infection control) backed by research “Visual pollution” vs. visual cues: the case for ruthless editing (“de-crapification”) before adding signs Wayfinding that works under stress: step-by-step instructions, few decision points, and reassurance cues Designing for low literacy: a color-and-letter “subway” system, line-of-travel markers, and proximity intuition Pictograms that actually communicate: testing, swapping out abstractions, and kid-friendly icons Measuring ROI: missed appointments, staff disruptions, and the real cost of poor wayfinding In-house rhythm at a research hospital: tight feedback loops, quick iterations, and process fixes Donor walls that age well: digital storytelling, magnetic plaques, and durable substrates Advocacy and pipeline: AMFP Upstate NY, craft labor realities, and manufacturing shifts ahead Big wish list: self-cleaning floors (for hospitals…and home) Why post-occupancy evaluations could prevent future design disasters (and why they rarely happen) Key Takeaways Edit before you add. Wayfinding succeeds when clutter is removed and destinations are made legible through architecture, lighting, and contrast—not just more signs. Design for the stressed brain. Fewer decision points + stepwise reassurance beat complex directions every time. Evidence accelerates approvals. EBD turns subjective taste debates into science-backed decisions leadership can green-light. Symbols > sentences. Tested pictograms improve comprehension across languages, ages, and literacy levels. Iterate in the wild. Being embedded with clinicians and patients surfaces quick wins you'll never catch from afar. Memorable Quotes from Corinn Soro “Another sign isn't the answer—it dilutes the message.” “Wayfinding is about giving choice back to patients when so much else is out of their control.” “If a space is ‘too quiet' for the engineer, it's probably just right for the neonates.” “Healthcare design is a team sport.” Resources & Links Roswell Park Comprehensive Cancer Center — https://www.roswellpark.org/ AMFP Upstate New York Chapter — https://amfp.org/upstate-new-york Fiona Finer, the Interior Designer (ages 3–8) — https://www.amazon.com/Fiona-Finer-Interior-Designer-Corinn/dp/1720664889 EDAC Certification (Evidence-Based Design) — https://www.healthdesign.org/certification-outreach/edac Hablamos Juntos pictograms — https://www.theicod.org/resources/news-archive/segd-and-hablamos-juntos-introduce-new-universal-symbols-in-health-care Sisters of Charity Hospital (Buffalo, NY) — NICU project mentioned — https://www.chsbuffalo.org/sisters-of-charity-hospital/ Past HID2.0 episode featuring Tama Duffy Day — Episode 20 https://healthcareidpodcast.libsyn.com/2019/09 Connect with Corinn Soro Email: corinn.soro@roswellpark.org LinkedIn: https://www.linkedin.com/in/corinn-soro-14859ab/ Our Industry Partners The world is changing quickly. The Center for Health Design is committed to providing the healthcare design and senior living design industries with the latest research, best practices and innovations. The Center can help you solve today's biggest healthcare challenges and make a difference in care, safety, medical outcomes, and the bottom line.  Find out more at healthdesign.org. Additional support for this podcast comes from our industry partners: The American Academy of Healthcare Interior Designers The Nursing Institute for Healthcare Design Learn more about how to become a Certified Healthcare Interior Designer®  by visiting the American Academy of Healthcare Interior Designers at: https://aahid.org/. Connect to a community interested in supporting clinician involvement in design and construction of the built environment by visiting The Nursing Institute for Healthcare Design at https://www.nursingihd.com/ ------------ The world is changing quickly. The Center for Health Design is committed to providing the healthcare design and senior living design industries with the latest research, best practices and innovations. The Center can help you solve today's biggest healthcare challenges and make a difference in care, safety, medical outcomes, and the bottom line.  Find out more at healthdesign.org. Additional support for this podcast comes from our industry partners: The American Academy of Healthcare Interior Designers The Nursing Institute for Healthcare Design Learn more about how to become a Certified Healthcare Interior Designer®  by visiting the American Academy of Healthcare Interior Designers at: https://aahid.org/. Connect to a community interested in supporting clinician involvement in design and construction of the built environment by visiting The Nursing Institute for Healthcare Design at https://www.nursingihd.com/ FEATURED PRODUCT Porcelanosa are at the forefront of sustainable manufacturing – clients not only expect this of their suppliers but are increasingly asking to see the receipts. Let's unpack this, did you know that hundreds of preeminent members of The American Institute of Architects –  The AIA – have signed the AIA Materials Pledge? The Pledge is aligned with the Mindful Materials Common Materials Framework – the CMF. This is just one, very impressive example of how the movement to support decision making for building product selection has reached new highs. We can see these explained as 5 pillars of sustainability: (The first) - Human Health: Focusing on avoiding hazardous substances and promoting well-being. (Then) - Social Health & Equity: Addressing human rights and fair labor practices throughout the supply chain. (The third) is Ecosystem Health: Supporting the regeneration of natural resources and habitats. (This is followed by) Climate Health: Reducing and sequestering carbon emissions. (And the fifth pillar) is The Circular Economy: Promoting a zero-waste future through design for resilience, adaptability, and reuse. I mentioned the receipts -How do we track the progress of these principles and values? Without measurement, there's no clear path to improvement or accountability. The Mindful Materials CMF maps a framework of over 650 sustainability factors across those five key areas. A cornerstone of material health transparency is an Environmental Product Declaration EPD report. The best are independently verified for accuracy by third party certification bodies – a company cannot mark their own report cards. EPDs are highly technical documents containing scientific information on the embodied carbon used to manufacture products. I have just read and included here an EPD for a Porcelanosa Tile – there are upwards of 1000 data inputs to quantify its climate impact. Porcelanosa offer the confidence and certainty of knowing that every tile, every slab of XTONE porcelain or KRION solid surface  has a Product Specific EPD – when architects and designers work with these materials they are making a robust decision to meet their sustainable design goals. To learn more about how Porcelanosa help their customers design for resiliency, here is a link to their comprehensive Corporate Social Responsibility Report: https://www.porcelanosa.com/en/corporate-social-responsibility/

Rachel Cliffe, Community Outreach and Partnerships Manager at Siteman Cancer Center, discusses her role in cancer prevention and community education. She highlights the importance of healthy habits like eating well, exercising, and avoiding smoking to reduce cancer risk. Rachel shares her experience with recent partnerships with local businesses in St. Louis to help raise cancer awareness. Check out St. Louis Mom's latest reel of Ovarian Cancer Prevention in partnership with Siteman Cancer Center!This podcast episode is sponsored by Siteman Cancer Center: National Leaders in Cancer Treatment & Research.Rachel Cliffe is a Telly Award–winning producer at Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine, where she's spent seven years advancing the organization's mission to educate and empower the St. Louis community on cancer prevention and early detection. As Community Outreach & Partnerships Manager, Rachel develops innovative collaborations with local organizations, businesses, venues, and community groups to promote healthier lifestyles and raise awareness about the critical importance of early and routine cancer screenings. She also leads production of Siteman's award-winning podcast, ‘This Is Cancer', a patient-centered series featuring conversations with WashU Medicine physicians that aim to inform, uplift, and support individuals navigating cancer treatment, caregiving, and beyond. Outside of work, Rachel enjoys taking her kids to local parks, cooking, spending time with friends and family, and discovering new restaurants in St. Louis.We hope you enjoyed this podcast episode! To learn more about Moms of the Lou you can go to stlouismom.com or follow us on Instagram and Facebook. You can listen to the podcast on Apple Podcast and Spotify. And don't forget to rate and review so more people can tune in! This episode was produced by the St. Louis Mom. It was recorded and edited by STL Bucketlist Studios in St. Louis, Missouri. 

Time for a Check Up - Sean Sullivan talked to Director of Research Karla Childers from the Southern Cancer Center about the type of clinical trials.  

On this month's Time for a Check Up Sean Sullivan talked to Southern Cancer Center's Karla Childers about Clinical Trials.  Clinical trial are important to test medications that can help in the future!  How does it work??  Listen here:

The Kearney Regional Medical Center – owned by Bryan Health – and Cancer Partners of Nebraska are coming together to open the Kearney Cancer Center, a 25,000-square-foot facility dedicated to cancer treatment. The center includes a positron emission tomography (PET) scanner to detect early signs of cancer, a linear accelerator for delivering radiation to treat tumors, and infusion bays with views of Yanney Park for chemotherapy patients. It will also offer on-site lab and diagnostic imaging, access to national clinical trials and certified mastectomy fitting.

The Kearney Regional Medical Center – owned by Bryan Health – and Cancer Partners of Nebraska are coming together to open the Kearney Cancer Center, a 25,000-square-foot facility dedicated to cancer treatment. The center includes a positron emission tomography (PET) scanner to detect early signs of cancer, a linear accelerator for delivering radiation to treat tumors, and infusion bays with views of Yanney Park for chemotherapy patients. It will also offer on-site lab and diagnostic imaging, access to national clinical trials and certified mastectomy fitting.

Southern Remedy Healthy and Fit is hosted by Josie Bidwell, Professor of Preventive Medicine and Nurse Practitioner at UMMC. If you have a question for Josie, you can email fit@mpbonline.org. It this episode, Josie is joined by Dr. Justin Turner, community health office for the Cancer Center and Research Institute at UMMC to discuss prostate cancer. If you enjoy listening to this podcast, please consider contributing to MPB. https://donate.mpbfoundation.org/mspb/podcast. Hosted on Acast. See acast.com/privacy for more information.

Today, we’re bringing you the best from the KUOW Newsroom… The Fred Hutchinson Cancer Center celebrated its 50th anniversary this week - the center has evolved from a scrappy lab doing what some considered risky science, into one of the top cancer centers in the world. International students have brought needed revenue to colleges in recent years, especially community colleges where local enrollment has fallen… But getting permission to study in the U-S has gotten harder under the Trump administration. And September 2nd marked 80 years since the end of World War II. Hear from veterans’ families, and a historian working to preserve personal memories of World War II. We can only make Seattle Now because listeners support us. Tap here to make a gift and keep Seattle Now in your feed. Got questions about local news or story ideas to share? We want to hear from you! Email us at seattlenow@kuow.org, leave us a voicemail at (206) 616-6746 or leave us feedback online.See omnystudio.com/listener for privacy information.

Jennifer Connelly, MD, Neuro-Oncologist with Froedtert's Cancer Center and Professor at MCW, will discuss the rarity of brain tumors and advancements being made in their diagnosis and treatment. She'll share the science, stories, and the strength of a community fighting back, showing how early research, small donations, and shared knowledge are fueling hope and prolonging life expectancy.

In this week's HappyCast, Andrew and Stephanie sit down with returning guest Aimee Jacobs fresh off her run at the Leadville 100, joined by her pacer and close friend, Mel (“DJ Melly Mel”). From San Antonio to the Colorado Rockies, Aimee recounts her buildup to one of the most prestigious 100-mile races in the country, the challenges of training at altitude, and the unforgettable experience of racing at elevation. Mel shares how their friendship grew from early morning base runs to supporting each other through some of the toughest miles of their careers.Aimee opens up about the harsh realities of racing at altitude — coughing up blood at Silver Rush, the relentless GI struggles at Leadville, and even temporary vision loss near the finish. Yet, with Mel at her side, troubleshooting fuel, offering tough love, and even providing questionable DJ playlists, the two pushed through every setback. Listeners will laugh at stories of “the princess pooping her pants,” garden gnome good-luck charms, and Mel's accidental splits, while also being moved by the raw emotion of Aimee's finish and the strength of their bond.Looking ahead, Aimee talks about her bold jump into the world of 200-mile races, including Bigfoot 200 and the possibility of a Triple Crown attempt. She also shares her fundraising mission for Christus Children's Cancer Center, running not just for herself but for kids in need of care. Whether you're inspired by grit, friendship, or the sheer absurdity that comes with ultra-running, this episode captures the spirit of why we toe the line and keep coming back for more.Be sure to subscribe to the podcast wherever you listen, and we always appreciate you leaving a good rate and review. Join the Facebook Group and follow us on Instagram and check out our website for the more episodes, posts and merchandise coming soon. Have a topic you'd like to hear discussed in depth, or a guest you'd like to nominate? Email us at info@happyendingstc.org

Cancer isn't just random genetic mutations. It doesn't “just happen.” In this episode, Dr. Connealy pulls back the curtain on what really drives cancer — from mitochondrial breakdown and hidden toxins to stress, parasites, and even low voltage inside your cells. You'll learn how to hack your environment, strengthen your biology, and prevent disease years before a tumor ever shows up on a scan. Dr. Leigh Erin Connealy, MD, is one of the most sought-after integrative oncologists in the world. She runs the Cancer Center for Healing and the Center for New Medicine, where she's been upgrading patient outcomes for nearly four decades. Her new book, The Cancer Revolution, gives you the tools to take back control of your biology and stop cancer before it starts.What You'll Discover

Today on Sauna Talk, we welcome a very special guest. Dr. Hans Hägglund. Who is Dr. Hans Hägglund? Hans Hägglund MD, PhD, is a medical doctor and professor at Uppsala University, in Northern Sweden. Professor Hägglund has a strong research back ground in clinical research within medicine. He graduated from Karolinska institute, Sweden and did his post doc at Fred Hutchinson Cancer Research Center in Seattle, USA. Between 2013 and 2018 he served as the director of the Cancer Center at Uppsala University Hospital. Professor Hägglund also had the position as the national cancer coordinator at The Swedish Association of Local Authorities and Regions (SALAR) between 2019-2022. He currently holds a position as a senior consultant at Karolinska University Hospital in Stockholm, which is where we catch up with him for this episode of Sauna Talk. Hot facts On this episode of Sauna Talk, we recognize that Hans Hägglund is a man who wears many hats in the world of health, wellness, and sauna culture. Hans is an affiliated researcher at the Center for Resilient Health at the Stockholm School of Economics, and co-founder of Vision Zero Cancer in Sweden. Known by many as the “sauna doctor,” he serves at the Swedish Sauna Academy, sits on the board of the Sauna Research Institute and the International Sauna Association, and played a key role in organizing the XVII International Sauna Congress in Haparanda/Tornio back in 2018. His book The Sauna Book – Hot Facts on Sauna and Health, published in Swedish in 2020, has attracted wide attention for the way it bridges science and tradition. We explore why sauna and cold bathing are seeing a surge in global interest, and what challenges remain in researching their health benefits. Hans shares his thoughts on why sauna bathing should be considered alongside traditional medicine, gives us a glimpse into the new book he's writing, and reflects on how prevention can be far more cost-effective than treatment. Along the way, we discuss his professional journey, the boards he serves on, and even his earliest sauna memories. And, of course, we'll hear his take on one of my favorite questions: from a Swedish — and global — perspective, what's the most misunderstood thing about sauna that he wishes more people knew? Let's welcome Dr. Hans Hägglund to Sauna Talk. Here's a short intro for social medializing: “In this episode of Sauna Talk, I sit down with Hans Hägglund — “the sauna doctor” — affiliated researcher, co-founder of Vision Zero Cancer, and board member of the International Sauna Association. We dive into the rising global interest in sauna and cold bathing, the challenges of sauna research, and why prevention may be the most powerful medicine. Hans also shares personal sauna memories, his upcoming book project, and what he believes is the most misunderstood thing about sauna.” Punchy one sentences: From Swedish sauna congresses to cold plunges, Hans Hägglund brings the heat — and the science — to Sauna Talk. What's the most misunderstood thing about sauna? “The sauna doctor” Hans Hägglund has a prescription. Sauna, science, and a splash of cold water — Hans Hägglund joins Sauna Talk for a deep dive into the health of heat.

Breaking Barriers, Making Healthy Choices, and Embracing Survivorship Breaking Barriers, Making Healthy Choices, and Embracing Survivorship. In this episode Yonni and Heather sit down with Dr. Laurie Kirstein from Memorial Sloan Kettering Cancer Center, who made history as the first female chair of the American College of Surgeons' Commission on Cancer. We will talk about breaking glass ceilings, access to quality healthcare, pain management and the impact of smoking on women's health outcomes. Dr. Laurie Kirstein is an Attending Breast Surgeon at memorial string Cancer Center. She attended downstate medical school, Montefiore Medical Center/Albert Einstein University for residency and Massachusetts General Hospital for Breast Surgery fellowship. Prior to arriving at Memorial Sloan Kettering she was attending surgeon and Breast Fellowship Director at the Rutgers Cancer Center Institute of New Jersey. At Memorial SloanKettering she is the Surgical Site Director for their Monmouth, NJ location. She is the current Chair for the American College of Surgeon's Commission on Cancer. She is the lead for the national quality improvement project Breaking Barriers: overcoming barriers to cancer care across America. Her research interests include surgical decision for breast cancer, postoperative pain management and tobacco cessation for cancer patients. Find Yonni & Heather here https://www.herhealthcompass.com/

This episode features Joanna Weiss, Executive Vice President and CFO at Moffitt Cancer Center, who shares her journey through finance and revenue cycle leadership. She discusses key priorities including financial stabilization, strategic growth, AI-driven automation, and how the CFO role is evolving to support long-term innovation and patient-centered care.

TIME FOR A CHECK UP: On Midday Mobile Sean Sullivan talked to the new addition the Southern Cancer Center great team medical oncologist Dr. Jeff Caughran.  They discuss his background and move with his wife from Chattanooga.  Meet Dr Caughran listen here:

A local cemetery in Indianapolis has a new owner with plans to provide more holistic, inclusive funeral services. Indiana's only comprehensive cancer center could lose its National Cancer Institute designation if the state doesn't invest in cancer research. An analysis by the group Earthjustice shows some utilities and landowners might not be following toxic coal ash laws. Governor Mike Braun says Indiana got good news Tuesday as it closed the books on the last fiscal year with $2.5 billion in reserve – Democrats say the state is in budget purgatory. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org/news and follow us on social media to get comprehensive analysis and local news daily. Subscribe to WFYI News Now wherever you get your podcasts. WFYI News Now is produced by Drew Daudelin, Zach Bundy and Abriana Herron, with support from News Director Sarah Neal-Estes.

On Midday Mobile Sean Sullivan talked to Michelle Sanford Dean from Southern Cancer Center about advance care plans.  Southern Cancer Center has several different ways and treatments to treat cancer and can help you plan your treatment with your need in mind.  Listen to their conversation here;

In this episode, host D. J. Thatcher chats with Emily Z. Touloukian, DO, with Coastal Cancer Center.  She describes all the awesome assets of Coastal Cancer Center and the extra care they take with their patients.

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

News of President Biden's prostate cancer diagnosis raised both awareness and questions about how and when to communicate about a serious illness. How can patients access guidance and resources when it comes to understanding their emotions, while also sometimes needing to navigate those of friends and family? What is the role of supporters and caregivers? Our guests specialize in helping patients with these questions. They join us to share their expertise. In studio: Ronald Epstein, M.D., professor of family medicine, oncology, and medicine (palliative care) at the University of Rochester Medical Center Supriya Mohile, M.D., geriatric oncologist and professor in the Departments of Medicine, Hematology/Oncology; Surgery, Cancer Control; and the Cancer Center; and vice chair for academic affairs in the Department of Medicine at the University of Rochester Medical Center Abby Squicciarini, LMSW, oncology social work supervisor at Lipson Cancer Institute

On today's show we're excited to welcome Rick Peng, the Innovation Hub Manager and Digital Licensing Professional at Memorial Sloan Kettering Cancer Center. We talk about how your organization can build an outside-in, external innovation program to deliver outsized results. Rick breaks down the secret sauce of the MSK Innovation Hub, an accelerator program designed to encourage collaborations between Memorial Sloan Kettering Cancer Center and digital health companies, focused on the diagnosis, treatment, and care of cancer patients. We discuss their new Innovation Hub Challenge focused on AI Drug Discovery – and why the access to data sets, is a key unlock for ai driven solutions.

A new full-service cancer center opened in Lewistown this month. The nearly 17,000 square foot facility will offer radiation, chemo and other oncology services. It's the only facility like it within 100 miles.

TIME FOR A CHECK UP: On Midday Mobile Sean Sullivan talked to Dr. Eric Roberts, Southern Cancer Center's New General Surgeon.  Get to know the newest member of the team that is here for you!!  

My team at Moffitt Cancer Center helped save my life and I'm forever grateful for their brilliance, dedication, and friendship over the past 6+ years. This is a repost of the episode I did with them last year.  Being a guest on the PEP Talks podcast for providers and staff at Moffitt was an honor, a privilege, and a labor of love. Moffitt is an amazing place filled with amazing people dedicated to curing cancer.Side note: I know I've been off the radar for a couple of years -- life's been challenging and busy and full of good things. Meanwhile, in addition to my full-time job, I'm writing a book about dealing with cancer, developing public speaking opportunities, and working on arrangements for the apartment we just bought in Italy. It's been a lifelong dream and we're so excited! I'll do an episode about this in the not-to-distant-future, so you can come along for that process, as well. It's all part of the "etc." in "Life, Cancer, Etc."Keywords: Moffitt, H. Lee Moffitt Cancer Center, cancer diagnosis, sarcoma, cancerNote: I'm not a medical professional. Everyone in these podcasts is sharing their own experiences.You can also find some episodes on our YouTube channel: https://www.youtube.com/c/LifeCancerEtcYou can also find some episodes on our YouTube channel: https://www.youtube.com/c/LifeCancerEtc

TIME FOR A CHECK UP: On Midday Mobile Sean Sullivan talked to Dr. Meshad about a subject they have been discussing this month which is targeting and treating cancer with bispecific antibodies.   There are several new advances and Dr Meshad explains the treatments and success here:

President Joe Biden's cancer diagnosis has sparked a wave of concern, as well as questions about the disease. Who tends to get it? When should men get screened? What causes it? What are the myths, and what are the realities? Our guests answer questions from listeners about prostate cancer: Supriya Mohile, M.D., geriatric oncologist and professor in the Departments of Medicine, Hematology/Oncology; Surgery, Cancer Control; and the Cancer Center; and vice chair for academic affairs in the Department of Medicine at the University of Rochester Medical Center Thomas Osinski, M.D., assistant professor of urology at the University of Rochester Medical Center Matthew Truong, M.D., urologist who practices general urology and urologic oncology at the Center for Urology, which is associated with Rochester Regional Health

TIME FOR A CHECK UP  On Midday Mobile Sean Sullivan talked to Southern Cancer Center's Dr Meshad about new advancements in Cancer treatment.  Dr Meshad explained bispecific antibodies and the research that is helping his patients.  Through this treatment it turns antibodies against the Cancer.  Listen to their conversation here:

On Thursday's show: We learn about a $150 million donation that will create the Kinder Children's Cancer Center, a new initiative to fight childhood cancer at MD Anderson Cancer Center and Texas Children's Hospital. The gift is one of the largest such donations in the history of the Texas Medical Center and one of the largest ever given to a pediatric hospital in the country.Also this hour: Comedian Ramy Youssef performs Friday night at House of Blues, and he has a new animated series on Amazon Prime called #1 Happy Family USA! We revisit a 2019 conversation with him about how he got into comedy and about how much of his standup material and work on television has revolved around the experience of growing up Muslim in America.Then, a Houston mother lost her parental rights to her children for life because of allegations her ex-husband made in court. We learn why the Texas Supreme Court unanimously overturned that ruling and what it means for how protective orders are issued here.And Laura Walker visits a farm run by the Socialites Riding Network, a Black-owned nonprofit that teaches sustainable agriculture and an appreciation for animals.

Elizabeth Wild on the important work of the Hillman Cancer Center full 554 Tue, 13 May 2025 18:26:49 +0000 zIyyJsSTJ4cWTGGYouTOPJ12KigPYdIr upmc marty,news,a-newscasts,top picks Marty Griffin upmc marty,news,a-newscasts,top picks Elizabeth Wild on the important work of the Hillman Cancer Center On-demand selections from Marty's show on Newsradio 1020 KDKA , airing weekdays from 10 a.m. to 2 p.m. 2024 © 2021 Audacy, Inc. News News News News news News News News News News False https://player.amperwavepod

Send us a textThis podcast originally ran on October 15, 2024.Hotflash inc founder and host Ann Marie McQueen sits down with Dr Leigh Erin Connealy, a leading figure in integrative medicine, known for her unique approach in combining conventional and alternative treatments in addressing chronic illnesses and cancer. Dr Connealy is the founder of the Center for New Medicine and the Cancer Center for Healing in Irvine, California and author of two books: The Cancer Revolution and the Be Perfectly Healthy. She is also co-founder of leading hormone brand, Raena Health.She talks about why so many people are getting cancer, how to make chemotherapy more effective and less lethal, why prevention needs to be the focus. For Dr Connealy, the question we need to be asking: what is going on with your terrain, and why is it making cancer? Everything from the food we eat to the chemicals we surround ourselves with to the emotional work we aren't doing is causing this. And find out what she thinks our number one risk is – why and what we can do about it. (It's probably not what you are thinking)Dr Connealy wants us all to know that in most cases, cancer is 10 years in the making. She has really good guidance for women considering hormone therapy, explaining the differences in synthetic hormones and the importance of the “orchestra”, including progesterone and pregnanalone, and more than one kind of estrogen. She explains why there is no one solution that fits all women – even though that's what mainstream medicine wants us to believe – and gives guidance on the particular cocktail, with tweaks, that she likes to prescribe. She also gives her take on whether hormone therapy prevents cancer – its worth listening to the end just to hear what she has to say about that – and addresses that ongoing fear women have, which is weighing our fear of breast cancer risk when considering hormone therapy.Dr Connealy is recognized for her personalized, holistic approach. This episode is nothing short of a masterclass on how to get our inner house in order.Highlights:01:56 The importance of personalized medicine02:07 The rise of chronic diseases03:09 The need for preventive healthcare04:44 Challenges in cancer treatment13:08 The importance of self-care14:40 The impact of EMFs on health28:12 The power of essential oils28:46 Reprogramming the mind with EVOX29:41 Healing affirmations and subconscious reprogramming33:37 The importance of sleep and water purificationThe Living in Clarity Podcast, with Fish & Coach Do you want to live an awesome life and to also inspire others? Fish is a world...Listen on: Apple Podcasts SpotifyJoin the Hotflash inc perimenoposse: Web: hotflashinc.comNewsletter: Hotflash inc. on SubstackTikTok: @hotflashincInstagram: @hotflashincX: @hotflashinc Episode website: Hotflashinc Listen on: Apple Podcasts | Spotify | Google Podcasts | YouTube | Substack See hotflashinc.com/privacy-policy for privacy information

Time for a Check up: On Midday Mobile today Sean Sullivan talked to Dr. Michael Meshad about cancer treatment.  This week's topic was Bispecific Science.  Listen for their conversation here:

In this episode of The Patient From Hell, host Samira Daswani speaks with oncology nurse Joshua Carter about his path into cancer care, shaped by personal experiences with family illness. They explore the differences between palliative and hospice care, the complexities of pain management, and the vital role nurses play as advocates. Josh also discusses misconceptions around pain medication, the promise and challenges of e-health tools, and the often-invisible workflows nurses navigate daily. He shares practical advice for patients, caregivers, and fellow clinicians, emphasizing the importance of early palliative care and being a bold advocate within the healthcare system.About Our GuestJosh Carter is an Oncology Nurse at Stanford Women's Cancer Center. His entire 17-year nursing career has been in oncology, with inpatient, industry, and outpatient experiences in Cleveland, Chicago, San Diego, and San Francisco. Josh holds undergraduate degrees from Kent State University and Ohio University and is currently on track to complete his Master's at the University of Michigan School of Nursing this Fall. He is a certified Oncology and Breast Care Nurse. His interests include Nursing Innovation, Digital Health, Patient Advocacy, Patient Education, Patient-Centered Design, Healthcare Improvement, Quality, and Implementation Science. With his interests in Healthcare Quality, Josh is currently a Site Assessor for the Michigan Oncology Quality Consortium. Josh has spoken at the National Oncology Nursing Society Congress and Authored Chapters of Oncology Nursing Society Text Books. Josh has been involved with research for caregivers of Cancer patients and has helped in the launch of newly approved cancer treatments. Josh has experience working on a cancer care delivery team at ASCO and has been awarded the DAISY Award for Extraordinary Nurses. Resources & Links:This episode was supported by the Patient Centered Outcomes Research Institute (PCORI) and features the PCORI study “A Stepped-Wedge Randomized Controlled Trial: Effects of eHealth Interventions for Pain Control Among Adults With Cancer in Hospice”Sections00:00 - Journey into Oncology Nursing03:22 - Understanding Palliative vs. Hospice Care07:04 - Pain Management in Cancer Care10:23 - Pain Management Strategies and Misconceptions20:32 - E-Health Interventions in Pain Management23:19 - The Complex Workflow of Oncology Nursing27:48 - Quick Tips for Patients and CaregiversConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on instagram, facebook, or linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Listen Across Platform:Website: https://mantacares.com/pages/podcast?srsltid=AfmBOopEP5GJ-Wd2nL-HYAInrwerIVhyJw67salKT-r9Qb_gadBvbHie YouTube: https://www.youtube.com/@mantacares Spotify:  https://open.spotify.com/show/6gM1GxDBUgXrHwlO0Zvnzs?si=9edb8680461d4eaa Apple: https://podcasts.apple.com/us/podcast/patient-from-hell/id1622669098 Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.This episode was supported by an award from the Patient-Centered Outcomes Research Institute.

In this podcast, Dr. Tami Johnson and Dr. Anne Tucker discuss the AJHP Practice Research Report, “Pharmacy prevalence of second victim syndrome in a comprehensive cancer center,” with host and AJHP Editor in Chief Dr. Daniel Cobaugh.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this fascinating episode of the Project Purple Podcast, CEO & Founder Dino Verrelli welcomes Dr. Cosimo Commisso, interim director and deputy director of the NCI-designated Cancer Center at Sanford Burnham Prebys Medical Discovery Institute. A leader in cancer metabolism research, Dr. Commisso shares groundbreaking insights into how pancreatic cancer cells survive and thrive—and what that means for future treatments. Dr. Commisso breaks down the complex science behind tumor microenvironments, metabolic vulnerabilities, and the latest advances in targeting pancreatic cancer at a cellular level. He also discusses the challenges researchers face, the hope emerging from new studies, and why funding for this research is more critical than ever. Whether you're a patient, caregiver, advocate, or science enthusiast, this episode delivers a powerful look at the cutting edge of pancreatic cancer research and the fight for better treatments. Subscribe to the Project Purple Podcast for more inspiring stories. If you'd like to donate to Project Purple's mission of a world without pancreatic cancer, please visit https://www.projectpurple.org/. To learn more about Project Purple, visit https://www.projectpurple.org/ or follow us on social media at these links: https://www.facebook.com/Run4ProjectPurple https://www.instagram.com/projectpurple/ https://twitter.com/Run4Purple https://www.youtube.com/channel/UCgA8nVhUY6_MLj5z3rnDQZQ

Time for a Check up: On Midday Mobile Sean Sullivan talked to Reese Jones from Southern Cancer Center about Cancer Behavior.  He explains different behaviors and treatments. 

In this episode, Dr. Michelle F. DeVeau, Director of the Leadership Institute, and Dr. Amanda Woods, Associate Leadership Institute Analyst at MD Anderson Cancer Center, discuss their innovative coaching programs, the impact on leadership retention and development, and how data-driven strategies are shaping the future of coaching in healthcare organizations.

Danielle and Whitney sit down with the renowned Dr. Leigh Erin Connealy to understand how to take control of your control panel, your health and your life. Dr. Connealy discusses her personal stories with family, drugs and her road to becoming a doctor. As a doctor, Dr. Connealy tells us what doctors aren't telling us. She shares easy steps to understand if you have cancer, cancer prevention tips, and lifestyle support to thrive. She unveils how to find joy in healthcare decisions.  This episode was recorded in front of a virtual live audience as part of our Sakara Talk Series. Check out the video version on the Sakara Life YouTube channel here: https://youtu.be/fdsvS8DS_rQ  Dr. Connealy shares: The truths about cancer  How to be in control of your control panel How to not become your problem, but to take your problem as a learning opportunity to thrive The impact of sugar, anxiety and our longevity Epigenetics and top tips for staying healthy Holistic approach to hormones and hormone health  About Dr. Connealy: A leader in the Integrative Medicine space, Dr. Connealy is known for her patient-first approach and for her focus on preventing cancer through addressing patients and their lifestyle habits, rather than just the disease. She is the medical director of The Cancer Center for Healing and The Center for New Medicine which sees patients from all over the world. Dr. Connealy is the author of The Cancer Revolution and Be Perfectly Healthy, and for the past ten years, she has been named one of the top 50 integrative doctors in the country. Dr. Connealy's mission is to share her knowledge with her community to help others be in control of their control panel and live their best, and longest lives.

Dr. Leigh Erin Connealy is the world-renowned Medical Director and founder of the Center For New Medicine and Cancer Center for Healing, both located in Irvine, California. She is one of the top integrative and holistic cancer doctors in America. Alex asks about the increasing rates of cancer among people under 30, hidden toxins in tattoo ink, why a colonoscopy should NOT be your first choice, detoxing from parasites, and more. Thank you to our sponsors! Taylor Dukes Wellness | Use code "ALEXCLARK" for 10% OFF America's Christian Credit Union | Earn $100 bonus when you create a new account ⁠⁠YRefy⁠⁠ | Call (888) 502-2612 or visit ⁠⁠yrefy.com Cowboy Colostrum | Use code “ALEX” for 15% OFF Garnuu | Use code “ALEX” for 15% OFF A'del Natural Cosmetics | Use code "ALEX" for 25% OFF Leigh Erin Connealy, MD Instagram |@ConnealyMD TikTok | @connealymd Instagram | @centerfornewmedicine Instagram | @cancercenterforhealing Resources "The Cancer Revolution: A Groundbreaking Program to Reverse and Prevent Cancer" by Leigh Erin Connealy, MD Alex Clark Instagram | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@realalexclark⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@cultureapothecary⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@realalexclark⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ X | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@yoalexrapz⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ YouTube | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@RealAlexClark⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Spotify | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Culture Apothecary with Alex Clark ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Apple Podcast | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Culture Apothecary with Alex Clark⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ New 'Culture Apothecary' Merch OUT NOW! Glass tumblers, weekly wellness planners, hats, crewnecks and more. Use code "Alex Clark" for 10% OFF at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠tpusamerch.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Join the Cuteservatives Facebook group to connect with likeminded friends who love America and all things health and wellness! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Join the CUTEservative Facebook Group!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe to ‘Culture Apothecary' on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. New episodes drop 6pm PST/ 9pm EST every Monday and Thursday. This show is made possible with generous donations from listeners who believe in our mission to heal a sick culture. You can support our show by leaving a tax deductible donation ⁠HERE⁠ or by subscribing to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@RealAlexClark⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ YouTube for FREE! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ This episode is not intended to be a substitute for professional medical advice and is for informational purposes only. Consult your doctor with further questions. #cultureapothecary #alexclark #podcast  #health  #wellness